Profil
Mr. Patrick C.
Hutchison, CPA, is a Co-Founder, Partner at Boundary Street Capital LP, a Treasurer at TetraLogic Pharmaceuticals Corp.
and a Managing Director at Stonepeak Partners LP.
Mr. Hutchison was previously employed as a Chief Financial Officer by BioSpecifics Technologies Corp., a Chief Financial Officer by SwanBio Therapeutics, Inc., a Chief Financial Officer by Innocoll Holdings Plc, a Chief Financial Officer by Innocoll, Inc., a Vice President by Pacific Western Asset Management, Inc., a Chief Accounting Officer & VP-Corporate Controller by Teleflex, Inc., a Vice President by MCG Capital, a Controller by Cephalon, Inc., a Principal by Day & Zimmermann, Inc. (Pennsylvania), a Chief Financial Officer by InfraScan, Inc., and a Principal by Pierce Leahy Corp.
He received his undergraduate degree from the University of Pennsylvania.
Postes actifs de Patrick C. Hutchison
| Sociétés | Poste | Début |
|---|---|---|
| TETRALOGIC PHARMACEUTICALS CORPORATION | Treasurer | 30/04/2016 |
Boundary Street Capital LP
Boundary Street Capital LP Investment ManagersFinance Boundary Street Capital invests in lower middle market companies located in the United States. The firm targets companies operating in the fields of digital infrastructure, digital services and enterprise software sectors and industries. It provides financing for seed, early, late, growth stage capital requirements with a revenue ranging from USD 5 to 50 million. | Fondateur | 01/01/2018 |
Anciens postes connus de Patrick C. Hutchison
| Sociétés | Poste | Fin |
|---|---|---|
| BIOSPECIFICS TECHNOLOGIES CORP. | Directeur Financier/CFO | 02/12/2020 |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Directeur Financier/CFO | 01/12/2019 |
Innocoll, Inc.
Innocoll, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products and medical devices | Directeur Financier/CFO | 01/08/2018 |
Pacific Western Asset Management, Inc.
Pacific Western Asset Management, Inc. Investment ManagersFinance Provides investment advice | Private Equity Investor | 31/12/2017 |
MCG Capital
MCG Capital Investment ManagersFinance MCG Capital provides capital to support the growth and value creation strategies of small- to mid-sized companies. They invest in companies with $20 million to $200 million in revenue and $3 million to $25 million in EBITDA. The firm looks for companies with the following characteristics: proven business models, stable customer bases, operating leverage, barriers to entry, defensible market shares and quality management teams. They avoid highly cyclical and volatile industry sectors and businesses with extraordinary volatility exposure. | Private Equity Investor | 31/03/2014 |
Formation de Patrick C. Hutchison
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Teleflex, Inc.
Teleflex, Inc. Medical SpecialtiesHealth Technology Provides medical devices for critical care, urology and surgery | Health Technology |
BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. Pharmaceuticals: MajorHealth Technology Develops injectable collagenase clostridium histolyticum (CCH) for multiple indications | Health Technology |
Pierce Leahy Corp.
Pierce Leahy Corp. Other TransportationTransportation Record storage | Transportation |
InfraScan, Inc.
InfraScan, Inc. Medical SpecialtiesHealth Technology Develops and distributes diagnostic imaging devices | Health Technology |
TetraLogic Pharmaceuticals Corp.
TetraLogic Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that focuses on discovering and developing novel small molecule therapeutics in oncology and infectious diseases | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MCG Capital
MCG Capital Investment ManagersFinance MCG Capital provides capital to support the growth and value creation strategies of small- to mid-sized companies. They invest in companies with $20 million to $200 million in revenue and $3 million to $25 million in EBITDA. The firm looks for companies with the following characteristics: proven business models, stable customer bases, operating leverage, barriers to entry, defensible market shares and quality management teams. They avoid highly cyclical and volatile industry sectors and businesses with extraordinary volatility exposure. | Finance |
Day & Zimmermann, Inc. (Pennsylvania)
Day & Zimmermann, Inc. (Pennsylvania) Engineering & ConstructionIndustrial Services Provides engineering, architecture and facilities support services | Industrial Services |
Innocoll, Inc.
Innocoll, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products and medical devices | Health Technology |
Pacific Western Asset Management, Inc.
Pacific Western Asset Management, Inc. Investment ManagersFinance Provides investment advice | Finance |
Innocoll Holdings Plc
Innocoll Holdings Plc Pharmaceuticals: MajorHealth Technology Develops specialty pharmaceuticals | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Health Technology |
Boundary Street Capital LP
Boundary Street Capital LP Investment ManagersFinance Boundary Street Capital invests in lower middle market companies located in the United States. The firm targets companies operating in the fields of digital infrastructure, digital services and enterprise software sectors and industries. It provides financing for seed, early, late, growth stage capital requirements with a revenue ranging from USD 5 to 50 million. | Finance |
















